Managing Early Development Challenges in Drug Manufacturing

This white paper discusses the complexities and challenges associated with early development in drug manufacturing, particularly focusing on the path toward Investigational New Drug (IND) submission. It outlines insights from a roundtable discussion featuring product development experts who address the common pitfalls in early development strategies. The paper highlights the increasing pressure on timelines due to factors such as the pandemic's impact on the pharmaceutical supply chain and the rising costs of capital. It emphasizes the importance of flexibility and collaboration among teams to navigate these challenges effectively. Additionally, it details the significance of a phase-appropriate approach to drug development, ensuring that processes are tailored to meet the specific needs of early-stage projects. The paper also notes the necessity of re-evaluating analytical methods in response to changes in development processes, underscoring the critical nature of adaptability in achieving successful outcomes in drug development.